Evidence map›Paper›PMID 40825851›Full record

ArticleCell death and differentiation2026

TRIM32 promotes anoikis resistance and metastasis in NSCLC by degrading CHEK2 to enhance IL-6 secretion.

Jia Xu, Wenjun Liu, Li Chen, Juan Zhang, Dongze Zhang, Xue Huang, Guangbo Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jia XuJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Wenjun LiuJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Li ChenJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Juan ZhangJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Dongze ZhangJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xue HuangJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China. huangxue2021@suda.edu.cn.ORCID 0009-0004-4159-9758
Guangbo ZhangJiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China. zhangguangbo@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis significantly contributes to the high mortality of non-small cell lung cancer (NSCLC), with anoikis resistance playing a critical role in this process. However, the role of TRIM32 in anoikis resistance and metastasis is not well understood. In this study, we demonstrate that TRIM32 enhances both anoikis resistance and metastasis in NSCLC. We confirmed the interaction between TRIM32 and CHEK2, and showed that TRIM32 mediates the degradation of CHEK2 via K48-linked polyubiquitination. Our results indicate that CHEK2 suppresses anoikis resistance and metastasis in NSCLC, both in vitro and in vivo. Additionally, we found that TRIM32 upregulates IL-6 expression, an effect that is reversed by the overexpression of CHEK2. Further analysis confirmed that IL-6 plays a key role in TRIM32-mediated anoikis resistance and metastasis. Notably, TRIM32

Indexed as

AnoikisCarcinoma, Non-Small-Cell LungCheckpoint Kinase 2Interleukin-6Lung NeoplasmsTranscription FactorsTripartite Motif ProteinsUbiquitin-Protein LigasesAnimalsCell Line, TumorFemaleHumansMaleMiceMice, Inbred BALB CMice, NudeCheckpoint Kinase 2CHEK2 protein, humanIL6 protein, humanInterleukin-6Transcription FactorsTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID40825851
PMCPMC12811291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.